Denali Therapeutics Inc. filings document regulatory, financial and governance disclosures for a biotechnology company developing blood-brain-barrier-crossing therapeutics. Recent 8-K reports record operating results, FDA approval and launch-related disclosures for AVLAYAH™, clinical pipeline updates, and material events tied to collaboration agreements and royalty funding arrangements.
Denali’s proxy materials cover board matters, executive compensation, equity awards and shareholder voting items. Its event filings also describe capital-structure and financing obligations, Regulation FD disclosures, exhibit-based press releases, and formal updates on TransportVehicle-enabled programs across lysosomal storage and neurodegenerative disease indications.
A person named Carole Ho has filed a Rule 144 notice indicating an intention to sell 150,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists an aggregate market value of 3,176,970.00 for these shares and shows 146,661,833 shares outstanding.
The notice also reports that on 02/04/2026 options were exercised under a registered plan to acquire 36,042 and 113,958 common shares for cash. In the past three months, the same seller disposed of 150,000 common shares for 3,324,060.00.
A shareholder in DNLI has filed a notice of intent to sell 150,000 shares of common stock on the NASDAQ, with an aggregate market value of $3,324,060. The planned sales are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of February 3, 2026.
The shares were acquired on February 2, 2026 by exercising stock options under a registered plan, in three transactions for 22,042, 44,021, and 83,937 shares, all paid in cash. The filing notes that there were 146,661,833 shares of this class of stock outstanding.
Denali Therapeutics Inc. President and CEO Ryan J. Watts reported a sale of common stock in a Form 4 filing. On January 6, 2026, he sold 35,198 shares of Denali common stock at $16.50 per share, and the filing explains that these shares were sold to satisfy tax obligations related to the settlement of previously vested restricted stock units (RSUs). Following this transaction, he directly beneficially owned 296,833 shares, which include 184,915 unvested RSUs. The filing also reports an additional 2,152,604 shares held indirectly through the Watts Family 2015 Trust, for which he serves as trustee.
Denali Therapeutics Inc. officer Alexander O. Schuth, the company’s COFO and Secretary, reported a sale of common stock. On 01/06/2026, he sold 17,218 shares of Denali common stock at $16.5 per share, with the filing stating that the sale was made to satisfy his tax obligations related to the settlement of previously vested restricted stock units (RSUs). After this transaction, he beneficially owned 282,828 shares directly, which the filing notes includes 141,100 unvested RSUs. The filing also reports 523,749 shares held indirectly through The Schuth Family Trust U/A DTD 06/05/2017, for which he serves as trustee.
A shareholder of Denali Therapeutics Inc. has filed a notice of proposed sale under Rule 144 covering 35,198 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/06/2026 on the NASDAQ, with an aggregate market value listed as $580,767. The filing notes that these shares were acquired on 01/03/2026 through a restricted stock lapse described as equity compensation.
Denali Therapeutics Inc. filed a current report to share that it has issued a press release outlining an update on its programs and expected milestones for 2026, and its planned participation in the 44th Annual J.P. Morgan Healthcare Conference. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company notes that the information under Regulation FD in this report, including Exhibit 99.1, is being furnished rather than filed, which limits how it is treated under securities law.
Denali Therapeutics Inc. insiders affiliated with Baker Brothers reported large purchases of $0.01 prefunded warrants to buy the company’s common stock. On December 11, 2025, 667, L.P. acquired 190,523 prefunded warrants and Baker Brothers Life Sciences, L.P. acquired 2,095,191 prefunded warrants in a public offering at $17.49 per warrant. Each warrant is exercisable at any time on a 1-for-1 basis into common stock at an exercise price of $0.01 per share, with no expiration date.
These warrants can only be exercised to the extent the holders and their affiliates would beneficially own no more than 4.99% of Denali’s outstanding common stock, a cap that can be adjusted up to 19.99% with 61 days’ notice. After these transactions, 667, L.P. beneficially owned 2,335,469 prefunded warrants and Baker Brothers Life Sciences, L.P. beneficially owned 25,996,310 prefunded warrants. Julian C. Baker is a director of Denali, and other reporting persons are deemed directors by deputization through their board representation and advisory roles.
Denali Therapeutics (DNLI) filed a Form 4 for a director equity grant. On 11/04/2025, the director received 10,632 restricted stock units at $0 and was shown beneficially owning 10,632 common shares after the transaction, held directly.
The director was also granted a stock option for 31,897 shares at an exercise price of $14.92, expiring 11/04/2034. RSUs vest in four equal annual installments from the grant date, subject to service. Options vest 25% on November 4, 2026, with the remainder vesting monthly in equal 1/48 increments thereafter.
Denali Therapeutics (DNLI) reported an insider Form 3 for a board member. The filing identifies the reporting person as a Director and indicates it is filed by one reporting person. The event date is 11/04/2025. In the remarks, the filer states no securities are beneficially owned. The signature block shows execution on 11/06/2025 by attorney-in-fact.
Denali Therapeutics (DNLI) reported Q3 2025 results with a net loss of $126.9 million as operating expenses rose. Research and development was $101.95 million and general and administrative reached $35.48 million. Interest and other income was $10.53 million.
Liquidity remained anchored by cash and investments: cash and cash equivalents were $90.963 million, short‑term marketable securities $757.241 million, and long‑term marketable securities $24.703 million. Shares outstanding were 146,661,833 as of October 31, 2025; an additional 26,046,065 shares are issuable upon exercise of pre‑funded warrants at $0.01 per share, subject to beneficial ownership limits.
Pipeline updates: the BLA for tividenofusp alfa (DNL310) was accepted for priority review, and the PDUFA target date was extended to April 5, 2026. Denali completed enrollment in the Phase 1/2 DNL126 study supporting a potential accelerated path in MPS IIIA, with a Phase 3 confirmatory study being planned. Biogen completed enrollment in the Phase 2b LUMA study for BIIB122/DNL151.